Cellivery Therapeutics Inc
KOSDAQ:268600
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cellivery Therapeutics Inc
Cost of Revenue
Cellivery Therapeutics Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Cost of Revenue
-₩22.4B
|
CAGR 3-Years
-200%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Cost of Revenue
-₩2.1T
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Cost of Revenue
-₩16.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Cost of Revenue
-₩181.4B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Cost of Revenue
-₩12.8B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Cost of Revenue
-₩15.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Cellivery Therapeutics Inc
Glance View
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
See Also
What is Cellivery Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-22.4B
KRW
Based on the financial report for Jun 30, 2024, Cellivery Therapeutics Inc's Cost of Revenue amounts to -22.4B KRW.
What is Cellivery Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-46%
Over the last year, the Cost of Revenue growth was -58%. The average annual Cost of Revenue growth rates for Cellivery Therapeutics Inc have been -200% over the past three years , -46% over the past five years .
You don't have any saved screeners yet
